SAR445761 - belumosudil
Sponsors
Sanofi-Aventis Recherche & Developpement, Sanofi-Aventis Research & Development, Medical Center - University Of Freiburg
Conditions
CancerChronic graft versus host disease.Lung transplant rejectionchronic graft versus host diseasesteroid-refractory overlap syndrom Graft-versus-Host-Disease
Phase 1
Phase 1/2 trial evaluating isatuximab in combination with SAR445761 (belumosudil) and dexamethasone in relapsed or refractory multiple myeloma (RRMM)
RecruitingCTIS2024-514992-16-00
Start: 2021-03-31Target: 17Updated: 2026-01-23
An open-label, Phase 1/2, multicenter study of belumosudil in children aged 1 to <18 years requiring systemic treatment for active moderate-to-severe chronic graft versus host disease (cGVHD).
RecruitingCTIS2024-511508-18-00
Start: 2026-01-05Target: 23Updated: 2025-11-26
Phase 2
Phase 3
A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by open-label
extensions, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft
dysfunction (CLAD) following bilateral lung transplantation
RecruitingCTIS2023-503462-23-00
Start: 2023-12-28Target: 77Updated: 2025-12-18
A randomized, double-blind, multicenter, Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD)
Active, not recruitingCTIS2023-505394-32-00
Start: 2025-02-06Target: 157Updated: 2025-09-24